TCZ is a neutralizing antibody against IL-6 and IL-6R and blocks both classical and signal transduction pathways [36], and it is currently the most preferred IL-6 inhibitor in the treatment of patients with COVID-19/ARDS. The gene discussed is IL6R; the disease is acute respiratory distress syndrome.